Skip to main content
SpringerLink
Log in

Apolipoprotein A1 and Fibronectin Fragments as Markers of Cure for the Chagas Disease

  • Protocol
  • First Online:
T. cruzi Infection

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1955))

  • 1112 Accesses

Abstract

Chagas disease (CD), endemic from Latin America, affects more than 8 million people, and the disease keeps spreading around the world due to population migrations. The treatment options for CD are currently limited to two drugs, benznidazole (BZ) and nifurtimox (Nfx), which are often unsatisfactory in chronically infected patients. To date, the only accepted marker of the cure is seroconversion (the disappearance of Trypanosoma cruzi antibodies in the patient’s serum), which can take decades to occur, if ever. The lack of posttreatment test-of-cure often prevents appropriate patient counseling and limits the development of new drugs. Without a doubt, reliable biomarkers for parasitological cure are urgently needed. Several pieces of evidence suggest that apolipoprotein A1 and fibronectin fragments are produced during the infection as part of the process of T. cruzi cell invasion and can thus be used as its surrogate biomarkers. In this chapter, we present a standardized method to evaluate these fragments in serum using mass spectrometry and immunoblotting in CD patients for diagnosis, prognosis, and treatment assessment purposes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Stanaway JD, Roth G (2015) The burden of Chagas disease: estimates and challenges. Glob Heart 10(3):139–144

    Article  Google Scholar 

  2. Meymandi SK, Forsyth CJ, Soverow J, Hernandez S, Sanchez D, Montgomery SP, Traina M (2017) Prevalence of Chagas disease in the Latin American–born population of Los Angeles. Clin Infect Dis 64(9):1182–1188

    Article  Google Scholar 

  3. Conners EE, Vinetz JM, Weeks JR, Brouwer KC (2016) A global systematic review of Chagas disease prevalence among migrants. Acta Trop 156:68–78

    Article  Google Scholar 

  4. Muñoz J, Coll O, Juncosa T, Vergés M, del Pino M, Fumado V, Bosch J, Posada EJ, Hernandez S, Fisa R (2009) Prevalence and vertical transmission of Trypanosoma cruzi infection among pregnant Latin American women attending 2 maternity clinics in Barcelona, Spain. Clin Infect Dis 48(12):1736–1740

    Article  Google Scholar 

  5. Flores-Chávez M, Fernández B, Puente S, Torres P, Rodríguez M, Monedero C, Cruz I, Gárate T, Canavate C (2008) Transfusional chagas disease: parasitological and serological monitoring of an infected recipient and blood donor. Clin Infect Dis 46(5):e44–e47

    Article  Google Scholar 

  6. Fearon MA, Scalia V, Huang M, Dines I, Ndao M, Lagacé-Wiens P (2013) A case of vertical transmission of Chagas disease contracted via blood transfusion in Canada. Can J Infect Dis Med Microbiol 24(1):32–34

    Article  Google Scholar 

  7. de Lana M, Martins-Filho OA (2015) Revisiting the posttherapeutic cure criterion in Chagas disease: time for new methods, more questions, doubts, and polemics or time to change old concepts? Biomed Res Int 2015:652985

    Article  Google Scholar 

  8. Britto CC (2009) Usefulness of PCR-based assays to assess drug efficacy in Chagas disease chemotherapy: value and limitations. Mem Inst Oswaldo Cruz 104:122–135

    Article  CAS  Google Scholar 

  9. Schmit P-O, Vialaret J, Wessels HJ, van Gool AJ, Lehmann S, Gabelle A, Wood J, Bern M, Paape R, Suckau D (2017) Towards a routine application of top-down approaches for label-free discovery workflows. J Proteome 175:12–26

    Article  Google Scholar 

  10. Catherman AD, Skinner OS, Kelleher NL (2014) Top down proteomics: facts and perspectives. Biochem Biophys Res Commun 445(4):683–693

    Article  CAS  Google Scholar 

  11. Ndao M, Spithill TW, Caffrey R, Li H, Podust VN, Perichon R, Santamaria C, Ache A, Duncan M, Powell MR, Ward BJ (2010) Identification of novel diagnostic serum biomarkers for Chagas’ disease in asymptomatic subjects by mass spectrometric profiling. J Clin Microbiol 48(4):1139–1149

    Article  CAS  Google Scholar 

  12. Santamaria C, Chatelain E, Jackson Y, Miao Q, Ward BJ, Chappuis F, Ndao M (2014) Serum biomarkers predictive of cure in Chagas disease patients after nifurtimox treatment. BMC Infect Dis 14:302

    Article  Google Scholar 

  13. Miao Q, Santamaria C, Bailey D, Genest J, Ward BJ, Ndao M (2014) Apolipoprotein A-I truncations in Chagas disease are caused by cruzipain, the major cysteine protease of Trypanosoma cruzi. Am J Pathol 184(4):976–984

    Article  CAS  Google Scholar 

  14. Ouaissi M, Afchain D, Capron A, Grimaud J (1984) Fibronectin receptors on Trypanosoma cruzi trypomastigotes and their biological function. Nature 308(5957):380

    Article  CAS  Google Scholar 

  15. Miao Q, Ndao M (2014) Trypanosoma cruzi infection and host lipid metabolism. Mediat Inflamm 2014:902038

    Article  Google Scholar 

  16. La Flamme AC, Kahn SJ, Rudensky AY, Van Voorhis WC (1997) Trypanosoma cruzi-infected macrophages are defective in major histocompatibility complex class II antigen presentation. Eur J Immunol 27(12):3085–3094

    Article  Google Scholar 

  17. Wang S-H, Yuan S-G, Peng D-Q, Zhao S-P (2012) HDL and ApoA-I inhibit antigen presentation-mediated T cell activation by disrupting lipid rafts in antigen presenting cells. Atherosclerosis 225(1):105–114

    Article  CAS  Google Scholar 

  18. Prioli RP, Rosenberg I, Pereira ME (1990) High- and low-density lipoproteins enhance infection of Trypanosoma cruzi in vitro. Mol Biochem Parasitol 38(2):191–198

    Article  CAS  Google Scholar 

  19. Combs TP, Nagajyothi MS, de Almeida CJ, Jelicks LA, Schubert W, Lin Y, Jayabalan DS, Zhao D, Braunstein VL, Landskroner-Eiger S, Cordero A, Factor SM, Weiss LM, Lisanti MP, Tanowitz HB, Scherer PE (2005) The adipocyte as an important target cell for Trypanosoma cruzi infection. J Biol Chem 280(25):24085–24094

    Article  CAS  Google Scholar 

  20. Tanowitz HB, Scherer PE, Mota MM, Figueiredo LM (2017) Adipose tissue: a safe haven for parasites? Trends Parasitol 33(4):276–284

    Article  Google Scholar 

  21. Nagajyothi F, Weiss LM, Silver DL, Desruisseaux MS, Scherer PE, Herz J, Tanowitz HB (2011) Trypanosoma cruzi utilizes the host low density lipoprotein receptor in invasion. PLoS Negl Trop Dis 5(2):e953

    Article  CAS  Google Scholar 

  22. Johndrow C, Nelson R, Tanowitz H, Weiss LM, Nagajyothi F (2014) Trypanosoma cruzi infection results in an increase in intracellular cholesterol. Microbes Infect 16(4):337–344. https://doi.org/10.1016/j.micinf.2014.01.001. S1286-4579(14)00003-3 [pii]

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA (2002) Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov 1(9):683

    Article  CAS  Google Scholar 

  24. Ruiz-Lancheros E, Rasoolizadeh A, Chatelain E, Garcia-Bournissen F, Moroni S, Moscatelli G, Altcheh J, Ndao M (2018) Validation of Apolipoprotein A-1 and Fibronectin Fragments as Markers of Parasitological Cure for Congenital Chagas Disease in Children Treated With Benznidazole. Open Forum Infect Dis, vol 11. p ofy23

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Reference Centre for Parasitology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada

    Elizabeth Ruiz-Lancheros, Makan Golizeh & Momar Ndao

  2. Program in Infectious Diseases and Immunity in Global Health, Research Institute of the McGill University Health Centre, Montreal, QC, Canada

    Elizabeth Ruiz-Lancheros, Makan Golizeh & Momar Ndao

Authors
  1. Elizabeth Ruiz-Lancheros
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Makan Golizeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Momar Ndao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Momar Ndao .

Editor information

Editors and Affiliations

  1. INGEBI-CONICET, Buenos Aires, Argentina

    Karina Andrea Gómez

  2. UNSAM-CONICET, IIB-INTECH, San Martin, Buenos Aires, Argentina

    Carlos Andrés Buscaglia

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Ruiz-Lancheros, E., Golizeh, M., Ndao, M. (2019). Apolipoprotein A1 and Fibronectin Fragments as Markers of Cure for the Chagas Disease. In: Gómez, K., Buscaglia, C. (eds) T. cruzi Infection. Methods in Molecular Biology, vol 1955. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-9148-8_20

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-9148-8_20

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-9147-1

  • Online ISBN: 978-1-4939-9148-8

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation